These advances have been attributed to improvements in cancer prevention, increased cancer screening, and advance-es in early detection, risk stratification, anti-HER2 therapy, anti-ER therapy, anti-PI3K and anti-mTOR therapy, anti-PD1 immunotherapy, whole genome sequencing (WGS), whole exome sequencing (WES) and combination therapies [4–11]. The gene discussed is MTOR; the disease is cancer.